Showing 4221-4230 of 5957 results for "".
- Heidelberg Engineering Names Hartmut Becker Head of Global Saleshttps://modernod.com/news/heidelberg-engineering-names-hartmut-becker-head-of-global-sales/2481710/Heidelberg Engineering has introduced Hartmut Becker as new Head of Global Sales, effective April 2023. In his new role, he will be leading the company’s sales and distribution activities across the group, and is responsible for supporting Heidelberg Engineering’s direct sub
- Bausch + Lomb Acquires Blink OTC Eye Drops from J&J Visionhttps://modernod.com/news/bausch-lomb-acquires-blink-eye-drops-from-jj-vision/2481709/The latest in a string of major moves by Bausch + Lomb, the company announced it is purchasing the Blink product line of eye and contact lens
- Salvat Laboratories Initiates a Pediatric Study in Europe with SVT-15473 for the Treatment of Inflammation and Pain Following Ocular Surgeryhttps://modernod.com/news/salvat-laboratories-initiates-a-pediatric-study-in-europe-with-svt-15473-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery/2481707/Salvat Laboratories has initiated a new study with SVT-15473 clobetasol to treat inflammation and pain in patients undergoing ocular surgery. The trial will include children aged 0 to 3 years with cataracts, aiming to demonstrate the drug's safety in this population. Cataracts
- Mount Sinai Launches Center for Ophthalmic Artificial Intelligence and Human Healthhttps://modernod.com/news/mount-sinai-launches-center-for-ophthalmic-artificial-intelligence-and-human-health/2481706/The Icahn School of Medicine at Mount Sinai has launched the Center for Ophthalmic Artificial Intelligence and Human Health, the first-of-its-kind in New York and one of the first in the United States. The Center is dedicated to advancing artificial intelligence (AI) in the field of ophthalm
- Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Trial of ADX‑2191 in Patients with RPhttps://modernod.com/news/aldeyra-therapeutics-announces-improvement-from-baseline-in-retinal-function-in-phase-2-clinical-trial-of-adx2191-in-patients-with-rp/2481703/Aldeyra Therapeutics announced positive topline results from the phase 2 clinical trial of intravitreal ADX-2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa (RP). Relative to baseline, the clinical trial demonstrated statistically s
- Visgenx Announces Positive Results from a Key Translational Study for its Gene Therapy Candidate for Dry AMDhttps://modernod.com/news/visgenx-announces-positive-results-from-a-key-translational-study-for-its-gene-therapy-candidate-for-dry-amd/2481700/Visgenx announced positive data from a non-human primate study. The translational study used a single subretinal injection to deliver VGX-0111 (carrying an ELOVL2 transgene) to investigate whether VGX-0111 expresses in the target tissues and causes an increase in certain very long chain
- Ciliatech Presents 2-Year Postoperative Results on New Cilio-Scleral Surgical Approach for Treating Glaucomahttps://modernod.com/news/ciliatech-presents-2-year-postoperative-results-on-new-cilio-scleral-surgical-approach-for-treating-glaucoma/2481698/Ciliatech announced it will present the preliminary results of the second 2-year postoperative clinical trial (SAFARI II) on its Cilia-scleral Interposition Device (CID) during the World Glaucoma Congress, taking place this week. Ciliatech will present results showing sta
- FDA Does Not Approve Regeneron's High-Dose Aflibercepthttps://modernod.com/news/fda-does-not-approve-regenerons-high-dose-aflibercept/2481695/Citing "an ongoing review of inspection findings at a third-party filler," the FDA declined to approve Regeneron's aflibercept 8 mg for the treatment of patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).</
- Myra Vision Announces Funding to Advance Calibreye Surgical Treatment for Glaucoma Patientshttps://modernod.com/news/myra-vision-raises-money-to-advance-calibreye-surgical-treatment-for-glaucoma-patients/2481694/Myra Vision, which is a Shifamed portfolio company, announced the closing of its $25 million Series B financing to further product development, scale manufacturing capabilities, and support first-in-human investigation of the company's Calibreye System, a novel treatm
- iOR Publishes Ophthalmic Office-Based Surgery Safety Studyhttps://modernod.com/news/ior-publishes-ophthalmic-office-based-surgery-safety-study/2481693/Office-based lens surgery can be performed safely, with adverse event rates similar to or lower than those in the published literature, according to a study published by iOR Partner